Sun Pharmaceutical Industries Limited (Sun Pharma) has achieved a significant milestone in dermatology with the Australian Therapeutic Goods Administration (TGA)’s recent approval of Winlevi (clascoterone cream 1%). Indicated for the topical treatment of acne vulgaris in patients aged 12 and older, Winlevi introduces a novel mechanism of action to the Australian market, enriching Sun Pharma’s […]
In a significant development within the field of medical dermatology, LEO Pharma A/S, a global leader renowned for its commitment to advancing dermatological care, presented key findings from the DELTA 3 trial at the prestigious 82nd American Academy of Dermatology (AAD) Congress in San Diego, California. This marks the first public disclosure of the results […]
LEO Pharma, a leading Danish pharmaceutical company, has acquired global exclusive rights to the atopic dermatitis drug JW1601 from JW Pharmaceutical (JWP), in a significant deal valued at approximately KRW 450 billion ($402 million). This licensing agreement, however, excludes South Korea, where JWP will retain exclusive rights. Under the terms of the agreement, LEO Pharma […]